TRANSITION AGREEMENTTransition Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
[*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information.
TERMINATION AND ASSET TRANSFER AGREEMENTTermination and Asset Transfer Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
This FIRST AMENDMENT TO THE TERMINATION AND ASSET TRANSFER AGREEMENT (this “Amendment”) is entered into as of January 19, 2015 (the “Amendment Date”) by and between Novartis Pharma AG, a Swiss corporation (“Novartis”); Novartis International Pharmaceutical Ltd., a corporation organized and existing under the laws of Bermuda, for purposes of Article II, Section 4.1, Section 5.1(d) and Article X only of the Agreement (as defined below) (“NIP”); and Array BioPharma Inc., a Delaware corporation (“Array”).
SEVENTH AMENDMENT TO DRUG DISCOVERY COLLABORATION AGREEMENTDrug Discovery Collaboration Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 7 (“Seventh Amendment”), effective as of the Settlement Effective Date (defined below) (“Amendment Date”), is entered into by and between Genentech, Inc., a Delaware corporation, having a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”) and Array BioPharma Inc., a Delaware corporation, having a principal place of business at 3200 Walnut Street, Boulder, Colorado 80301 (“Array”), (collectively, the “Parties” or individually, a “Party”).
TRANSITION AGREEMENTTransition Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
[*] Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. Confidential treatment has been requested with respect to this information.
LGX818 ASSET TRANSFER AGREEMENT by and between NOVARTIS PHARMA AG and ARRAY BIOPHARMA INC. Dated as of January 19, 2015Asset Transfer Agreement • May 7th, 2015 • Array Biopharma Inc • Pharmaceutical preparations • New York
THIS ASSET TRANSFER AGREEMENT, dated as of January 19, 2015 (together with all Schedules and Exhibits attached hereto, this “Agreement”), is made by and between Novartis Pharma AG, a Swiss corporation (“Novartis”), and Array BioPharma Inc., a Delaware corporation (“Array”).
